Sacubitril/Valsartan vs ACE Inhibitors or ARBs
Background: Sacubitril/valsartan (SAV) is crucial for managing heart failure (HF). Randomized clinical trials have shown SAV's superiority over angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) in reducing N-terminal pro-B-type natriuretic peptide levels....
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | JACC: Advances |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772963X25000158 |